MedTrace Logo

Effect of Tiotropium on Inflammation and Exacerbations in COPD

NCT00405236 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2006-11-29

No results posted yet for this study

Summary

Patients with COPD experience exacerbations that are a major cause of morbidity. Exacerbations are associated with increased airway and systemic inflammation and those experiencing frequent exacerbations demonstrate increased inflammation in the stable state. Tiotropium has been shown to reduce exacerbation frequency and it might be postulated that this is due to a reduction in inflammation. The study will compare airway inflammation and exacerbation frequency in patients with COPD on tiotropium or placebo.

Conditions

Interventions

DRUG

tiotropium

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Royal Free and University College Medical School

    lead OTHER

Principal Investigators

  • Jadwiga A Wedzicha, MD · Academic Unit of Respiratory Medicine, Royal Free and University College Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2005-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405236 on ClinicalTrials.gov